Skip to main content

Table 1 Emerging targets with clinical significance in urothelial carcinoma

From: Emerging therapeutic agents for genitourinary cancers

Molecular target Class Trial Disease setting Agent Experimental treatment Study phase Estimated completion
PD-1/PD-L1 CPI NCT02807636
(IMvigor130)
Untreated mUC Atezolizumab Atezolizumab + (Carboplatin)
(Gemcitabine)
(Cisplatin)
Phase III November 2020
NCT02853305
(Keynote-361)
Untreated mUC Pembrolizumab Pembrolizumab + (Cisplatin)
(Carboplatin)
(Gemcitabine)
Phase III May 2020
CTLA-4 NCT02516241
(DANUBE)
Untreated mUC Tremelimumab Durvalumab + tremelimumab or durvalumab monotherapy Phase III September 2019
CD122 Cytokine Modulation NCT02983045
(PIVOT-2)
Advanced tumors (mUC) NKTR-214 NKTR-214 + nivolumab or NKTR-214 + nivolumab + ipilimumab Phase I/II June 2021
NCT03785925
(Pivot-10)
Cisplatin-ineligible, mUC patients with low PD-L1 expression NKTR-214 NKTR-214 + nivolumab Phase III May 2022
NCT03138889
(PROPEL)
Advanced tumors (mUC) NKTR-214 NKTR-214 + pembrolizumab or NKTR-214 + atezolizumab Phase I May 2020
IL-7 NCT03513952 Advanced, inoperable or mUC CYT107 CYT107 + atezolizumab Phase I December 2020
TGFβ + PD-1 NCT02517398 Advanced tumors (mUC) MSB0011359C (M7824) MSB0011359C (M7824) Phase I August 2020
CD137/4-1BB NCT02845323 Cisplatin-ineligible MIBC Urelumab Urelumab + nivolumab or nivolumab monotherapy Phase II January 2020
OX40 NCT02554812
(JAVELIN Medley)
Advanced tumors (mUC) PF-04518600 Avelumab
Utomilumab
PF-04518600
PD 0360324
Phase II December 2020
NCT03217747 Advanced tumors (UC) PF-04518600 Avelumab
UtomilumabPF-04518600
Radiation
Cisplatin
Phase I/II August 2023
IDO T Cell Metabolism NCT03361865
(Keynote-672)
(ECHO307)
Cisplatin-ineligible UC Epacadostat Epacadostat + pembrolizumab Phase III September 2020
NCT03374488
(Keynote-698)
Cisplatin-ineligible mUC Epacadostat Epacadostat + pembrolizumab Phase III August 2020
VEGF TKI NCT03133390 Cisplatin-ineligible mUC Bevacizumab Bevacizumab + atezolizumab Phase II January 2020
NCT03272217 Cisplatin-ineligible untreated mUC Bevacizumab Bevacizumab + atezolizumab Phase II April 2021
cMET/VEGF NCT02717156 Untreated mUC EphB4-HSA EphB4-HAS + pembrolizumab Phase II November 2020
NCT03534804
(PemCab)
Cisplatin-ineligible mUC Cabozantinib Cabozantinib + pembrolizumab Phase II September 2023
NCT03170960 Advanced tumors (UC) Cabozantinib Cabozantinib + atezolizumab Phase I/II December 2020
FGFR NCT02546661
(BISCAY)
Previously-treated MIBC AZD4547
MEDI4736
Olaparib
AZD1775
Vistusertib
AZD9150
Selumetinib
Phase Ib March 2020
NCT03123055
(FIERCE-22)
mUC Vofatamab Vofatamab + pembrolizumab Phase I/II September 2022
NCT03473756
(FORT-2)
FGFR-positive mUC Rogaratinib Rogaratinib + atezolizumab Phase Ib/II July 2022
Nectin-4 ADC NCT03288545
(EV-103)
mUC Enfortumab Vedotin Enfortumab vedotin + pembrolizumab Phase I September 2024
NCT03219333
(EV-201)
mUC previously-treated with CPI Enfortumab Vedotin Enfortumab vedotin Phase II May 2025
NCT02091999 Nectin-4-positive mUC Enfortumab Vedotin Enfortumab vedotin Phase I December 2020
NCT03474107
(EV-301)
Previously-treated mUC Enfortumab Vedotin Enfortumab vedotin Phase III September 2021
HER-2 NCT03523572 mUC Trastuzumab Deruxtecan
(DS-8201a)
Trastuzumab
Deruxtecan
(DS-8201a)
Phase I/II September 2020
  1. All trial information obtained through publicly accessible clinicaltrials.gov